^
Association details:
| Biomarker: | CD38 expression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | BHV-1100 (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.
Published date:
05/28/2020
Excerpt:
A statistically significant increase in specific killing was observed when KP1237 was used in combination with CIML NK cells in an ADCC assay against CD38 expressing MOLP-8 (p = 0.0105, mean 61.8 ± SD 9.1 and mean 83.7 ± SD 13.58 for CIML NK alone and CIML NK+KP1237, respectively).
DOI:
10.1200/JCO.2020.38.15_suppl.8523
